MRNA Stock Price and Chart — BCBA:MRNA

Overview

Financials News Ideas Discussions Technicals Seasonals

Key facts today

Moderna won a legal battle against Pfizer and BioNTech over its COVID-19 vaccine patent. A court ordered Pfizer and BioNTech to reveal revenue from Moderna's patented technology.

Analysts predict Moderna's revenue forecasts are about 20% lower than expected, and they doubt the company will reach its 2028 cash break-even target, despite planned R&D savings.

Moderna (MRNA) is currently rated by two brokerages as 'buy' or higher, while seven have a 'hold' rating, and one rates it as 'underperform', with a median price target set at $54.51.

Analyze the impact Analyze the impact

About Moderna, Inc.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.